Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melphalan + cladribine + busulfan + cyclophosphamide
- Development stage
- Phase 2
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MCBC is an intensified conditioning regimen developed for patients with refractory or relapsed acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The regimen is a combination of four agents: melphalan, cladribine, busulfan, and cyclophosphamide. It is designed to enhance the anti-leukemic effect and improve outcomes compared to standard conditioning regimens like busulfan and cyclophosphamide (Bu/Cy). Melphalan, busulfan, and cyclophosphamide are alkylating agents that induce DNA damage and cell death in leukemic cells, while cladribine is a purine nucleoside analog that inhibits DNA synthesis and repair, potentially sensitizing cells to the effects of the alkylating agents. This combination is primarily being evaluated by the Institute of Hematology & Blood Diseases Hospital in China to improve recurrence-free survival in high-risk AML patients.
- Other names
- MCBC regimenMCBC conditioning regimen
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on melphalan + cladribine + busulfan + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melphalan + cladribine + busulfan + cyclophosphamide.